Mrinalini Dey
@DrMiniDey
Clinical Research Fellow @KCLImmunoMicro•Rheumatology Registrar•@EMEUNET rep to EULAR-PARE•Editorial Board @RheumJnl•#Comorbidities #SocialDeterminantsOfHealth
Delighted to share our paper on #multimorbidity in #RA emphasising a need for: -Operationalised definition of MM -Clearer distinction between MM & #comorbidity in literature -Greater understanding of MM to encourage holistic care @RheumJnl @ElenaNikiUK academic.oup.com/rheumatology/a…
#EULAR2025: busy but brilliant! Discussed #HealthLiteracy in 3 abstracts & #syndemics SG. Great to see #HealthInequalities highlighted! Loved helping organise the #EMEUNET X PARE speed-dating & chairing PARE fatigue session Lots of great science! Bring on London #EULAR2026!
In Munich 🇩🇪 today with the @eular_org #PARE committee, working already on topics like the November Conference or 2026 EULAR Congress!
Catch up on #RheumatoidArthritis highlights from #EULAR2025 with the @RheumNow round-up! A pleasure to discuss all things RA with RheumNow Royalty, Drs John Cush, @Janetbirdope & Jonathan Kay. Watch here: lnkd.in/dbZA2WHU Listen here: lnkd.in/dTkzKhUW
EULAR 2025 – RA Panel Discussion Leading experts in rheumatology dive into the latest advances, treatment strategies, and emerging research in rheumatoid arthritis. Don’t miss this in-depth panel as they unpack key findings from EULAR 2025 and discuss what’s next for RA care.…
🦋 Thank you to @DrMiniDey from RheumNow for this great interview on #LupusGPT & #EasyLupus! Don’t miss our Chair, @Jeanette_Lupus, and Zoe Karakikla-Mitsakou (General Secretary) as they reveal the story behind these innovative AI tools! youtube.com/watch?feature=…
🤩So excited about this interview! 💻#LupusGPT was winning awards at #EULAR2025 🎙️Delighted to meet with Zoe & @Jeanette_Lupus from @LupusEurope to find out about this exciting development in patient information & use of #AI in #rheumatology @RheumNow youtu.be/Iq4w7pwF0f8?fe…
Going live in 10 minutes! Recap of the #RheumatoidArthritis at #EULAR2025, live on @YouTube via @RheumNow Watch via the link below: youtube.com/watch?v=QCy-5-…
🌟The #EMEUNET meets #PARE speed dating was very insightful and inspiring for both rheumatologists and researchers! 🌟 #EMEUNET #EULAR2025
A pleasure to once again organise the @EMEUNET X PARE speed dating, this yr expertly curated by @krystelaouad! There was such a buzz & I was delighted to discuss #SharedDecisionMaking &treatment adherence with our fantastic patients. Thanks to all involved! #EULAR2025 @RheumNow
Discussion about Shared decision making and treatment adherence at The EMEUNET meets PARE speed dating #EULAR2025 #EMEUNET
🕵🏻 Did you do the escape rooms at #EULAR2025? 🙏🏼⭐️ Huge thanks to @cr_calomarde & @ugara96 who organised and curated this fantastic activity! 🧩🔎 Much needed downtime, educational & something different between the lectures & talks! 👏🏼 Congrats & thank you! @RheumNow
Our last year trainees (Dr Ugena & Dr Calomarde) have organized the funniest escape room in #EULAR ! Congrats for the amazing game and for the great success! We're really proud of you! 🥰#EMEUNET @emeunet #EULAR2025
Thank you #EULAR #PARE for the invitation to chair this important session. I learnt a lot and we really could have kept the discussions going for a long time! #EULAR2025
#EULAR2025 #PARE #Highlights: The Sleep Struggle: Navigating Fatigue in RMDs, chaired by @DrMiniDey and Marcos Séneca
APEX Phase 3b trial: #guselkumab (Q4W or Q8W) reduces joint damage in #PsA ✅ ACR20: 67–68% vs 47% (PBO) ✅ ↓radiographic progression (vdH-S: 0.55/0.54 vs 1.35) No new safety signals identified. @RheumNow #EULAR2025 #LB0010
In a 1st-in-human trial, allogeneic CD19 CAR-NK cell therapy was safe and effective in severe refractory #SLE. No neurotoxicity or ≥G2 CRS. At 12m, 67% achieved DORIS remission, 75% LLDAS. An alternative to autologous #CART? @RheumNow #EULAR2025 #LB0009
🦵🏻SAP-001, a novel uricosuric targeting a non-URAT1 renal transporter, lowered sUA <6 mg/dL in up to 79% of patients with refractory #gout on b/g xanthine oxidase inhibitor. >50% on 60 mg/day reached sUA <3 mg/dL. 💊Potential new oral ULT option. @RheumNow #EULAR2025 #LB0008
💉Early results from a dose-escalation trial of novel CD19xCD3xCD28 trispecific antibody (CC312) in refractory #SLE show no ICANS or ≥G2 CRS, rapid B cell depletion & 100% SRI-4 response (n=5). @RheumNow #EULAR2025 #LB0007 #CART
In RCT of RA pts in remission/low disease activity, spacing ozoralizumab (next gen TNFi) or reducing MTX led to more flares vs continued tx; but most pts in remission at baseline maintained LDAS. Remission matters for subsequent Tx reduction. @RheumNow #EULAR2025 #LB0006
RepurpSS-II RCT (n=46): LEF + HCQ significantly improved systemic disease activity (ESSDAI -4.13) vs PBO in primary #Sjögrens. ⭐️🌱STAR/CRESS response rates also favoured active treatment. Safe, accessible, affordable option for active disease. @RheumNow #EULAR2025 #LB0005
🌳#WILLOW: TLR7/8 inhibition with enpatoran led to greater BICLA response, IFN signature reduction & skin improvement (CLASI-50/70) in active SLE vs placebo at 24wks. Most benefit seen in pts with high IFN-GS or GC use. Good tolerability. @RheumNow #EULAR2025 #LB0004
🫁 In autoimmune ILD patients from FIBRONEER-ILD (n=325), nerandomilast slowed FVC decline vs placebo and reduced risk of ILD progression events (HR 0.56 for 18 mg BID). Acceptable safety profile & tolerability. @RheumNow #EULAR2025 #LB0003
📱 Axia, a digital therapeutic for #axSpa, led to significant improvements in BASDAI, BASFI & ASQoL in a 12-week RCT. ASAS20: 51% vs 9%; ASAS40: 23% vs 3%. Promising app-based intervention comprising individualised exercise, pt education & disease Mx. @RheumNow #EULAR2025 #LB0002